Cord blood is the residual blood left in a baby’s umbilical cord and placenta post birth. This cord blood is a rich source of hematopoietic stem cells and can be used for treating life-threatening conditions of the blood and immune system. Hematopoietic stem cells possess the potency to differentiate into different blood cell types.

The banking of cord blood stem cells involves the following processes: post-birth collection, processing, and cryopreservation in a cord blood bank.

Hematopoietic stem cells: Diseases stem cells can cure

Hematopoietic stem cells are currently utilised for treating more than 80 medical conditions which include diseases of the immune system, blood disorders, neurological disorders, metabolic disorders, genetic disorders, and several types of cancers like leukaemia, lymphoma, etc. For some of these conditions, stem cells are the primary treatment option.

Umbilical cord blood cells possess an immense therapeutic potential and are currently under dynamic progression for the expansion of their usage in treating several other life-threatening disorders. In spite of their potential in treating several conditions, patients frequently face extreme challenges while searching for a matching stem cell unit for treatment.

Endless waiting periods in search of a suitable matching donor are often reported as the prime reason for patient mortality. Currently, public stem cell banks available in India have only a limited number of stem cell units ready for therapeutic usage. The available stem cell units for transplant are extremely low compared to the treatment demands. The first public bank in India, Jeevan (also known as had shut down in 2017 due to funding issues.

Although bone marrow transplant can be used as an alternative for the treatment, here again, the bone marrow registry falls short in meeting the requirement of the patients. Lack of HLA matching and the prospective donor backing out due to the fear of surgical procedures are some of the critical challenges for this alternative.

During your baby’s birth, nature bestows a lifetime opportunity to bank your baby’s precious cord blood- a rich source of stem cells. LifeCell’s Community Stem Cell Banking gives you the opportunity to collect, preserve, and access your baby’s precious cord blood stem cells. This in future will be potent enough to protect your baby, entire family, and the community at large.

Some of the major advantages of cord blood transplants include economical option compared to bone marrow transplant, low immunological rejection rate, less risk for transmission of any infection, quick availability, no donor associated risks and easy collection process.

>LifeCell also conducts a stringent HLA matching procedure before releasing the stem cell units for transplant. Moreover, LifeCell is the first cord blood bank globally to introduce GenomeScope. GenomeScope is a panel of screening test for inherited diseases and pediatric cancers conducted on stem cell units before releasing them for transplant to ensure patient’s safety. Therefore, if you are expecting a baby, consider banking your baby’s cord blood with LifeCell. This, in turn, will shield your baby and entire family for a lifetime!

Clinical Trials

With recent advancements in umbilical cord blood stem cells research and development, cord blood cells have reached a zenith of being recognized as a potential source of regenerative therapy. Cord blood stem cells have been proven to be therapeutically potent for treating several haematological disorders. During late 2011, the US Food and Drug Administration has approved the first licensed cord blood stem cell therapy for treating hematopoietic disorders.

Cord blood cells are primarily regarded as a rich source of hematopoietic stem cells. However, there are several studies and reports that claim the potency of cord blood cells to differentiate into different cell lineages. Ever expanding in vitro and in vivo trials are being conducted to support the application of cord blood stem cells as a regenerative therapy for non-haematological disorders. Currently, several clinical trials are also conducted for both haematological and non-haematological disorders ranging from liver cirrhosis (NCT01224327*) to brain injury (NCT03696745*) to analyze the therapeutic impact of umbilical cord blood stem cells. Depending on the disease type and status, a number of clinical trials are on board to assess the therapeutic potency of stem cells to depress the disease progression & unlock new therapeutic avenues which are currently unavailable.

Some of the clinical trials are also targeted towards pre-established and approved stem cell therapies. Such trials are specifically conducted to determine certain parameters like the ideal candidate for the stem cell therapy, optimum dosage of stem cells and mode of delivery, etc.

Several other unascertained critical factors determine the therapeutic success of stem cell therapy. A number of clinical trials are in progress to elucidate how these regenerative therapies can be implemented to achieve clinically significant outcomes for both haematological and non-haematological disorders.

Some of the diseases or disorders which are currently undergoing umbilical cord blood stem cells based clinical trials are enlisted below

Diseases that can be cured by stem cells

  • Advanced Hematopoietic Malignancies
  • Blood Cancers
  • Sickle Cell Disease
  • Diabetes, Type 1 & 2
  • Ulcerative Colitis
  • Brain Injury
  • Liver Cirrhosis
  • Duchenne muscular dystrophy (DMD)
  • Idiopathic Dilated Cardiomyopathy
  • Diabetes-Related Vascular Complications
  • Hereditary Ataxia
  • Severe Aplastic Anaemia (SAA)
  • Autism
  • Psoriasis
  • Acute Cerebral Infarction
  • Immunodeficiency Diseases
  • Crohn's Disease
  • Fanconi Anaemia
  • Osteoarthritis
  • Spinal cord injury
  • Rheumatoid arthritis
  • Myelodysplastic Syndromes
  • Bronchopulmonary Dysplasia
  • Peripheral Arterial Disease
  • Osteonecrosis
  • Leukaemia
  • Lymphoma
  • Myelodysplastic Syndromes
  • Diabetic Foot Ulcer (DFU)
  • Multiple Sclerosis


  1. Search of: umbilical cord stem cells - List Results - [Internet]. [Cited 2019 May 29]. Available from:
  2. Factors Influencing the Umbilical Cord Blood Stem Cell Industry: An Evolving Treatment Landscape - Dessels - 2018 - STEM CELLS Translational Medicine - Wiley Online Library [Internet]. [Cited 2019 May 29]. Available from:
  3. Umbilical cord blood stem cells: clinical trials in non-hematological disorders | British Medical Bulletin | Oxford Academic [Internet]. [Cited 2019 May 29]. Available from:
  4. Umbilical cord blood stem cells: clinical trials in non-hematological disorders | British Medical Bulletin | Oxford Academic [Internet]. [Cited 2019 May 29]. Available from:
  5. Doctors’ Opinion on Cord Blood Banking | CBR® [Internet]. [Cited 2019 May 29]. Available from:
  6. What is cord blood used for today? | ViaCord [Internet]. [Cited 2019 May 29]. Available from:
  7. Cord Blood Clinical Processing, Cryopreservation, and Storage | Springer Link [Internet]. [Cited 2019 May 29]. Available from:
  8. Cryopreservation of Hematopoietic Stem Cells [Internet]. [Cited 2019 May 29]. Available from:
  9. Cord Blood Banking - ACOG [Internet]. [Cited 2019 May 29]. Available from:
  10. The Power of Stem Cells | California’s Stem Cell Agency [Internet]. [Cited 2019 May 29]. Available from:
  11. Stem Cell Therapy & Treatment - Diseases and Conditions [Internet]. [Cited 2019 May 29]. Available from:
  12. What are umbilical cord stem cells? - Stem Cells Australia [Internet]. [Cited 2019 May 29]. Available from:
  13. Stem Cells in the Umbilical Cord [Internet]. [Cited 2019 May 29]. Available from:
  14. Umbilical Cord Blood Banking: Consensus Statement of the Indian Academy of Pediatrics [Internet]. [Cited 2019 May 29]. Available from:
  15. LifeCell - India’s First and Largest Stem Cell Bank [Internet]. [Cited 2019 May 29]. Available from: